

# Stefan Agewall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5718323/publications.pdf>

Version: 2024-02-01

225  
papers

63,651  
citations

44444

50  
h-index

2453

203  
g-index

236  
all docs

236  
docs citations

236  
times ranked

55447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
2	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
3	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	1.4	4
4	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	1.5	22
5	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 1-3.	1.4	1
6	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	2.7	3
7	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. <i>Journal of Women's Health</i> , 2022, 31, 310-320.	1.5	2
8	Optimizing individual heart failure treatment. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	1.4	0
9	Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis. <i>PLoS ONE</i> , 2022, 17, e0264628.	1.1	4
10	Future of Antithrombotic Therapy for Heart Failure with Coronary Artery Disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	1.4	0
11	Focus on different aspects of atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 323-324.	1.4	1
12	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
13	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	1.7	26
14	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. <i>American Heart Journal</i> , 2021, 231, 96-104.	1.2	49
15	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	1.4	10
16	Different aspects of giving the optimal antiplatelet treatment. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 169-170.	1.4	1
17	Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. <i>PLoS ONE</i> , 2021, 16, e0253793.	1.1	4
18	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6

#	ARTICLE	IF	CITATIONS
19	Adherence to pharmacological treatment: how can we improve?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 261-262.	1.4	1
20	Fluoroquinolone use and valvular heart disease: is the jury still out?. European Heart Journal, 2021, 42, 2909-2911.	1.0	1
21	Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis. PLoS ONE, 2021, 16, e0253247.	1.1	10
22	More knowledge about atrial fibrillation, still we need to learn. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 361-362.	1.4	1
23	Early Comprehensive Cardiovascular Magnetic Resonance Imaging in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries. JACC: Cardiovascular Imaging, 2021, 14, 1774-1783.	2.3	46
24	Plasma catecholamine levels in the acute and subacute stages of takotsubo syndrome: Results from the Stockholm myocardial infarction with normal coronaries 2 study. Clinical Cardiology, 2021, 44, 1567-1574.	0.7	13
25	Unsolved pharmacological issues with cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 461-462.	1.4	0
26	Antiplatelet treatment in coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 81-82.	1.4	3
27	Atrial fibrillation in registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 1-2.	1.4	1
28	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. European Journal of Preventive Cardiology, 2020, 27, 234-243.	0.8	10
29	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 104-114.	1.4	25
30	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 86-93.	1.4	27
31	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 97-103.	1.4	14
32	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
33	Focus on pharma in acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 1-2.	1.4	0
34	Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome?. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 201-202.	1.4	2
35	Minimizing bleeding events. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 271-272.	1.4	6
36	Focus on subpopulations of atrial fibrillation patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 131-132.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
38	Lipids and antithrombotic treatment. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 71-71.	1.4	1
39	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	1.4	4
40	MSc in clinical trials: a new flagship Working Group project. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 284-284.	1.4	1
41	Focus on blood pressure and risk factor intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 339-340.	1.4	1
42	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
43	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
44	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
45	Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study. <i>PLoS ONE</i> , 2019, 14, e0220079.	1.1	16
46	European Heart Journal " Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 183-184.	1.4	0
47	Medical Misinformation: Vet the Message!. <i>Journal of the American Heart Association</i> , 2019, 8, e011838.	1.6	15
48	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure " A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019, 289, 83-90.	0.8	10
49	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46
50	Antiplatelet treatment in acute coronary syndrome. Still an issue. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 125-126.	1.4	6
51	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	1.2	7
52	Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries. <i>Clinical Chemistry</i> , 2019, 65, 1023-1030.	1.5	18
53	Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. <i>European Heart Journal Supplements</i> , 2019, 21, A28-A33.	0.0	20
54	Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e891-e908.	1.6	519

#	ARTICLE	IF	CITATIONS
55	European Heart Journal â€“ Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 59-59.	1.4	0
56	EJ Cardiovascular Pharmacotherapy has Impact Factor. <i>European Heart Journal</i> , 2019, 40, 572-572.	1.0	0
57	Unsolved issues in oral anticoagulation treatment in atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 60-61.	1.4	4
58	ST-segment elevation and cardiac magnetic resonance imaging findings in myocardial infarction with non-obstructive coronary arteries. <i>International Journal of Cardiology</i> , 2019, 287, 128-131.	0.8	17
59	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019, 105, 1252-1259.	1.2	18
60	Ivabradine for heart failure: regulatory differences in Europe and United States. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 119-121.	1.4	0
61	AB0343â€¦ANTIRHEUMATIC THERAPY IS NOT ASSOCIATED WITH CHANGES IN CIRCULATING N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP) LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
62	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.5	6
63	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	1.4	7
64	Old and new drugs in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 1-2.	1.4	2
65	Personality Traits in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. <i>American Journal of Medicine</i> , 2019, 132, 374-381.e1.	0.6	11
66	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 47-54.	1.4	16
67	Hyperkalemia and Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2019, 5, 130-132.	1.2	3
68	Cardiovascular pharmacotherapy and real-world data. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 65-66.	1.4	5
69	Cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 1-1.	1.4	6
70	Antiarrhythmic drugsâ€“clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732an.	0.7	144
71	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	1.0	16
72	Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 49, 91-97.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113
74	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 82-92.	1.4	11
75	Plasma biomarker levels and non-obstructive coronary artery disease determined by coronary computed tomography angiography. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 246-253.	0.5	6
76	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
77	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
78	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
79	Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, e35-e41.	1.0	16
80	The burden of heart failure in the general population: a clearer and more concerning picture. <i>Journal of Thoracic Disease</i> , 2018, 10, S1934-S1937.	0.6	13
81	Adherence to guidelines, compliance to treatment, and treatment quality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 189-190.	1.4	2
82	New input on antiplatelet treatment and registry studies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 129-130.	1.4	1
83	Critical appraisal of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 191-192.	1.4	5
84	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018, 272, 260-266.	0.8	24
85	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
86	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	1.0	1,396
87	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
88	Prevalence of Anxiety and Depression Symptoms in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries. <i>American Journal of Medicine</i> , 2018, 131, 1118-1124.	0.6	37
89	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
90	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. <i>European Heart Journal</i> , 2017, 38, ehw149.	1.0	511

#	ARTICLE	IF	CITATIONS
91	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRs). <i>Europace</i> , 2017, 19, euw242.	0.7	67
92	Anticoagulation, atherosclerosis, and heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 1-2.	1.4	2
93	New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. <i>European Journal of Internal Medicine</i> , 2017, 40, e11-e12.	1.0	4
94	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
95	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 711-721.	1.5	27
96	Effect of Myocardial Infarction With Nonobstructive Coronary Arteries on Physical Capacity and Quality-of-Life. <i>American Journal of Cardiology</i> , 2017, 120, 341-346.	0.7	39
97	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	0.8	5
98	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. <i>International Journal of Cardiology</i> , 2017, 249, 274-281.	0.8	1
99	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
100	Metabolic control, anticoagulation, and gender aspects. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 125-126.	1.4	1
101	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRs). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
102	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
103	Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>PLoS ONE</i> , 2017, 12, e0169830.	1.1	20
104	Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 232.	1.6	50
105	Adherence to guidelines and registry data. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 183-184.	1.4	17
106	<i>European Heart Journal - Cardiovascular Pharmacotherapy</i> . <i>European Heart Journal</i> , 2017, 38, 3251-3251.	1.0	1
107	Morphine in acute heart failure. <i>Journal of Thoracic Disease</i> , 2017, 9, 1851-1854.	0.6	11
108	The application to MEDLINE from <i>European Heart Journal-Cardiovascular Pharmacotherapy</i> has been accepted!. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 207-208.	1.4	0

#	ARTICLE	IF	CITATIONS
109	New ESC/ EACTS Guidelines for the management of atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 3, pvw038.	1.4	15
110	Cardiovascular pharmacotherapy. International Journal of Cardiology, 2016, 224, 412-415.	0.8	0
111	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
112	Troponin and exercise. International Journal of Cardiology, 2016, 221, 609-621.	0.8	120
113	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 108-118.	1.4	35
114	Update from EHJ CVP. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 77-78.	1.4	0
115	News from EHJCVP. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 141-141.	1.4	0
116	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	0.8	683
117	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. European Journal of Preventive Cardiology, 2016, 23, 194-205.	0.8	74
118	Morphine in myocardial infarction: balancing on the tight rope. European Heart Journal, 2016, 37, 253-255.	1.0	7
119	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal, 2016, 37, 1015-1023.	1.0	109
120	Second year of a journal. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 1-2.	1.4	0
121	Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 3-4.	1.4	0
122	Morphine in the treatment of acute pulmonary oedema – Why?. International Journal of Cardiology, 2016, 202, 870-873.	0.8	32
123	End of story? Studies on prevention of reperfusion injury encounter perpetual defeats. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 46-47.	1.4	3
124	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. European Heart Journal, 2015, 36, 2677-2680.	1.0	131
125	European Heart Journal – CVP: what is next?. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 73-73.	1.4	0
126	Cardiovascular Pharmacotherapy is moving!. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 149-149.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015, 17, 1144-1151.	2.9	84
128	Starting up a new Journal within the European Heart Journal Family. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 213-213.	1.4	0
129	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 169, 257-265.e1.	1.2	33
130	Risk Factors and Markers for Acute Myocardial Infarction With Angiographically Normal Coronary Arteries. <i>American Journal of Cardiology</i> , 2015, 116, 838-844.	0.7	47
131	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. <i>International Journal of Cardiology</i> , 2015, 196, 133-138.	0.8	19
132	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 887-896.	1.6	20
133	European Heart Journal " Cardiovascular Pharmacotherapy": a new journal within the European Heart Journal family. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 1-1.	1.4	0
134	How to save six million people per year. <i>Atherosclerosis</i> , 2015, 240, 387-388.	0.4	0
135	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	2.0	357
136	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	0.8	28
137	Neither endothelial function nor carotid artery intima-media thickness predicts coronary computed tomography angiography plaque burden in clinically healthy subjects: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 63.	0.7	5
138	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	0.7	635
139	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 31-36.	1.4	30
140	Troponins in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 78-84.	0.5	32
141	Re: Ulike retningslinjer for behandling av prostatakreft. <i>Tidsskrift for Den Norske Laegeforening</i> , 2015, 135, 1337-1337.	0.2	0
142	Relationship Between Oxidized LDL, IgM, and IgG Autoantibodies to ox-LDL Levels With Recurrent Cardiovascular Events in Swedish Patients With Previous Myocardial Infarction. <i>Angiology</i> , 2014, 65, 932-936.	0.8	10
143	Conventional treatment after myocardial infarction in routine clinical practice results in regression of left common carotid intima-media thickness. <i>Clinical Physiology and Functional Imaging</i> , 2014, 34, 322-326.	0.5	1
144	The early diastolic myocardial velocity: a marker of increased risk in patients with coronary heart disease. <i>Clinical Physiology and Functional Imaging</i> , 2014, 34, 389-396.	0.5	0

#	ARTICLE	IF	CITATIONS
145	“Troponin Elevation in Coronary Ischemia and Necrosis”; Current Atherosclerosis Reports, 2014, 16, 396.	2.0	9
146	Sick leave and a smoking ban. European Heart Journal, 2014, 35, 266-267.	1.0	3
147	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. European Heart Journal, 2014, 35, 2001-2009.	1.0	274
148	Subclinical Atherosclerosis, Endothelial Function, and Serum Inflammatory Markers in Chronic Kidney Disease Stages 3 to 4. Angiology, 2014, 65, 443-449.	0.8	16
149	Obstructive sleep apnea: no independent association to troponins. Sleep and Breathing, 2014, 18, 351-358.	0.9	6
150	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
151	Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea. Sleep Medicine, 2014, 15, 762-768.	0.8	4
152	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal, 2013, 34, 1708-1713.	1.0	159
153	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. International Journal of Cardiology, 2013, 167, 1772-1782.	0.8	67
154	Thyroid Dysfunction in Patients With Myocardial Infarction With Normal Coronary Arteries. Angiology, 2013, 64, 245-246.	0.8	0
155	Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection. Journal of Cardiovascular Pharmacology, 2013, 61, 250-257.	0.8	15
156	Some Aspects of Preventing Coronary Heart Disease. Angiology, 2012, 63, 17-23.	0.8	5
157	Risk Factors for Myocardial Infarction With Normal Coronary Arteries and Myocarditis Compared With Myocardial Infarction With Coronary Artery Stenosis. Angiology, 2012, 63, 500-503.	0.8	32
158	Echogenicity of the carotid intima-media complex and cardiovascular risk factors. Clinical Physiology and Functional Imaging, 2012, 32, 400-403.	0.5	10
159	Ultrasound and radiology surrogate endpoints in pharmacological studies. Atherosclerosis, 2012, 224, 12-24.	0.4	7
160	Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis, 2012, 224, 324-325.	0.4	12
161	Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with Rheumatoid Arthritis Treated with Methotrexate and TNF- $\alpha$ Inhibitors. Journal of Rheumatology, 2012, 39, 1341-1347.	1.0	12
162	Low self-estimated quality of life after myocardial infarction and future cardiovascular risk. International Journal of Cardiology, 2012, 157, 128-129.	0.8	5

#	ARTICLE	IF	CITATIONS
163	Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. <i>Clinica Chimica Acta</i> , 2012, 413, 933-937.	0.5	15
164	2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 93.	2.7	11
165	Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience. <i>Clinical Laboratory</i> , 2012, 58, 1029-36.	0.2	3
166	Diagnostic value of high sensitive troponin T in chest pain patients with no persistent ST-elevations. <i>Scandinavian Cardiovascular Journal</i> , 2011, 45, 198-204.	0.4	15
167	Gender differences among Norwegian patients with heart failure. <i>International Journal of Cardiology</i> , 2011, 146, 354-358.	0.8	24
168	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	1.0	2,995
169	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
170	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	1.0	1,394
171	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
172	Oral antiplatelet agents in ACS: from pharmacology to clinical differences. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 564-571.	1.0	8
173	Troponin elevation in coronary vs. non-coronary disease. <i>European Heart Journal</i> , 2011, 32, 404-411.	1.0	502
174	Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 606-612.	1.0	37
175	Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 151-158.	1.4	14
176	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 812-817.	0.5	101
177	Fysisk anstrengelse kan gi høye troponinverdier. <i>Tidsskrift for Den Norske Lægeforening</i> , 2011, 131, 2226-2226.	0.2	4
178	Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. <i>Clinical Laboratory</i> , 2011, 57, 615-8.	0.2	8
179	Matrix Metalloproteinases in Atherothrombosis. <i>Progress in Cardiovascular Diseases</i> , 2010, 52, 410-428.	1.6	164
180	Effect of Angiotensin-Converting Enzyme Inhibition on One-Year Mortality and Frequency of Repeat Acute Myocardial Infarction in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 105, 1229-1234.	0.7	45

#	ARTICLE	IF	CITATIONS
181	Impact of physical activity and body composition on heart function and morphology in middle-aged, abdominally obese women. <i>Clinical Physiology and Functional Imaging</i> , 2010, 30, 354-359.	0.5	14
182	Intima-media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction. <i>Echocardiography</i> , 2010, 27, 651-658.	0.3	4
183	COPD Predicts Mortality in HF: The Norwegian Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, 225-229.	0.7	65
184	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
185	Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. <i>Heart and Vessels</i> , 2009, 24, 90-95.	0.5	22
186	Expression of heat shock proteins and nitrotyrosine in small arteries from patients with coronary heart disease. <i>Heart and Vessels</i> , 2009, 24, 260-266.	0.5	12
187	Interpreting clinical trials: the "Beautiful" case. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 261-262.	1.0	1
188	Prothrombin fragment 1+2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. <i>Thrombosis Research</i> , 2009, 124, 526-530.	0.8	7
189	Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. <i>Atherosclerosis</i> , 2009, 202, 330-344.	0.4	148
190	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	1.0	735
191	Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. <i>International Journal of Cardiology</i> , 2008, 123, 195-196.	0.8	5
192	Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. <i>Atherosclerosis</i> , 2008, 196, 49-58.	0.4	39
193	Acute and stable coronary heart disease: different risk factors. <i>European Heart Journal</i> , 2008, 29, 1927-1929.	1.0	19
194	Quality of life and insulin resistance in patients with coronary heart disease. <i>Coronary Artery Disease</i> , 2008, 19, 289-292.	0.3	3
195	Gender issues in cardiovascular medicine. <i>Gynecological Endocrinology</i> , 2007, 23, 363-365.	0.7	0
196	Levosimendan: Perpetuum mobile?. <i>European Heart Journal</i> , 2007, 28, 515-515.	1.0	1
197	The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2249-2255.	1.2	87
198	Disturbed glucose metabolism is associated with left ventricular dysfunction using tissue Doppler imaging in patients with myocardial infarction. <i>Clinical Physiology and Functional Imaging</i> , 2007, 27, 60-66.	0.5	6

#	ARTICLE	IF	CITATIONS
199	Usefulness of Troponin Levels Below the Diagnostic Cut-Off Level for Acute Myocardial Infarction in Predicting Prognosis in Unselected Patients Admitted to the Coronary Care Unit. <i>American Journal of Cardiology</i> , 2007, 99, 1357-1359.	0.7	12
200	Endothelial function in conduit and resistance arteries in men with coronary disease. <i>Atherosclerosis</i> , 2006, 184, 130-136.	0.4	19
201	Atorvastatin normalizes endothelial function in healthy smokers. <i>Clinical Science</i> , 2006, 111, 87-91.	1.8	25
202	Matrix metalloproteinases and cardiovascular disease The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2006, 27, 121-122.	1.0	40
203	Intima-media complex of both the brachial artery and the common carotid artery are associated with left ventricular hypertrophy in patients with previous myocardial infarction. <i>Journal of Hypertension</i> , 2005, 23, 119-125.	0.3	15
204	The new definition of myocardial infarction-Can we use it?. <i>Clinical Cardiology</i> , 2005, 28, 77-80.	0.7	6
205	How should we evaluate an open artery in STEMI patients?. <i>European Heart Journal</i> , 2005, 26, 634-636.	1.0	6
206	Interrelation between the extent of atherosclerosis in the thoracic aorta, carotid intima-media thickness and the extent of coronary artery disease. <i>Atherosclerosis</i> , 2005, 179, 311-316.	0.4	116
207	Effect of tissue harmonic imaging and contrast upon between observer and test-retest reproducibility of left ventricular ejection fraction measurement in patients with heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 85-93.	2.9	13
208	Non-invasive assessment of endothelial function - relation between vasodilatory responses in skin microcirculation and brachial artery. <i>Clinical Physiology and Functional Imaging</i> , 2004, 24, 317-322.	0.5	77
209	Reduced quality of life after myocardial infarction in women compared with men. <i>Clinical Cardiology</i> , 2004, 27, 271-274.	0.7	47
210	Should oral glucose tolerance test be a routine examination after a myocardial infarction?. <i>International Journal of Cardiology</i> , 2004, 97, 21-24.	0.8	13
211	Snus is not Harmless!. <i>European Journal of Epidemiology</i> , 2003, 19, 819.	2.5	1
212	Evaluation of point-of-care test systems using the new definition of myocardial infarction. <i>Clinical Biochemistry</i> , 2003, 36, 27-30.	0.8	21
213	Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?. <i>Current Vascular Pharmacology</i> , 2003, 1, 107-109.	0.8	26
214	Microalbuminuria and intima-media thickness of the carotid artery in clinically healthy men. <i>Atherosclerosis</i> , 2002, 164, 161-166.	0.4	26
215	Urinary albumin excretion and insulin metabolism in clinically healthy 58-year-old men. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 750-753.	1.5	0
216	Post-occlusion brachial artery vasodilatation after ischaemic handgrip exercise is nitric oxide mediated. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 18-23.	0.5	24

#	ARTICLE	IF	CITATIONS
217	Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. <i>Clinical Cardiology</i> , 2002, 25, 287-290.	0.7	10
218	Chlamydia pneumoniae Seropositivity Is Associated With Carotid Artery Intima-Media Thickness. <i>Stroke</i> , 2000, 31, 1526-1531.	1.0	45
219	Chlamydia pneumoniae but Not Cytomegalovirus Antibodies Are Associated With Future Risk of Stroke and Cardiovascular Disease. <i>Stroke</i> , 1999, 30, 299-305.	1.0	172
220	Stroke Was Predicted by Dimensions of Quality of Life in Treated Hypertensive Men. <i>Stroke</i> , 1998, 29, 2329-2333.	1.0	30
221	Usefulness of Microalbuminuria in Predicting Cardiovascular Mortality in Treated Hypertensive Men With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 1997, 80, 164-169.	0.7	175
222	Multiple Risk Intervention in High-Risk Hypertensive Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 462-470.	1.1	29
223	Risk Factors That Predict Development of Microalbuminuria in Treated Hypertensive Men. <i>Angiology</i> , 1996, 47, 963-972.	0.8	14
224	Atherosclerotic Disease in the Femoral Artery in Hypertensive Patients at High Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 971-977.	1.1	33
225	Carotid Artery Wall Intima-Media Thickness Is Associated With Insulin-Mediated Glucose Disposal in Men at High and Low Coronary Risk. <i>Stroke</i> , 1995, 26, 956-960.	1.0	90